NCT05703516 - A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

OTHER

Capmatinib

There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis

Trial Locations (12)

16499

RECRUITING

Novartis Investigative Site, Suwon

42602

RECRUITING

Novartis Investigative Site, Daegu

519763

RECRUITING

Novartis Investigative Site, Jeollanam

02447

RECRUITING

Novartis Investigative Site, Seoul

06591

RECRUITING

Novartis Investigative Site, Seoul

602-030

RECRUITING

Novartis Investigative Site, Busan

302-241

RECRUITING

Novartis Investigative Site, Daejeon

405 760

RECRUITING

Novartis Investigative Site, Incheon

02841

RECRUITING

Novartis Investigative Site, Seoul

05505

RECRUITING

Novartis Investigative Site, Seoul

06273

RECRUITING

Novartis Investigative Site, Seoul

06351

RECRUITING

Novartis Investigative Site, Seoul